109 related articles for article (PubMed ID: 31839034)
21. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
Hatta Y; Mizuta S; Matsuo K; Ohtake S; Iwanaga M; Sugiura I; Doki N; Kanamori H; Ueda Y; Yoshida C; Dobashi N; Maeda T; Yujiri T; Monma F; Ito Y; Hayakawa F; Takeuchi J; Kiyoi H; Miyazaki Y; Naoe T
Ann Hematol; 2018 Sep; 97(9):1535-1545. PubMed ID: 29694642
[TBL] [Abstract][Full Text] [Related]
22. Susceptibility of Ph-positive all to TKI therapy associated with Bcr-Abl rearrangement patterns: a retrospective analysis.
Jing Y; Chen H; Liu M; Zhou M; Guo Y; Gao C; Wang Q; Li H; Zhao Y; Bo J; Huang W; Zhu H; Zhang Y; Yu L
PLoS One; 2014; 9(11):e110431. PubMed ID: 25415187
[TBL] [Abstract][Full Text] [Related]
23. [Risk Factors of Leukemia-free Survival in Ph
Bao XB; Cai WZ; He XF; Chen SN; Qiu HY; Sun AN; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1787-1792. PubMed ID: 29262917
[TBL] [Abstract][Full Text] [Related]
24. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
25. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).
Hanfstein B; Müller MC; Hehlmann R; Erben P; Lauseker M; Fabarius A; Schnittger S; Haferlach C; Göhring G; Proetel U; Kolb HJ; Krause SW; Hofmann WK; Schubert J; Einsele H; Dengler J; Hänel M; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Branford S; Hughes TP; Spiekermann K; Baerlocher GM; Pfirrmann M; Hasford J; Saußele S; Hochhaus A; ;
Leukemia; 2012 Sep; 26(9):2096-102. PubMed ID: 22446502
[TBL] [Abstract][Full Text] [Related]
26. Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A; Robak T; Pluta A; Zwolińska M; Wawrzyniak E; Wierzbowska A; Skotnicki A; Jakubas B; Hołowiecki J; Nowak K; Kuliczkowski K; Mazur G; Haus O; Dmoszyńska A; Adamczyk-Cioch M; Jedrzejczak WW; Paluszewska M; Konopka L; Pałynyczko G
Ann Hematol; 2006 Jun; 85(6):366-73. PubMed ID: 16523310
[TBL] [Abstract][Full Text] [Related]
27. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
Tavernier E; Le QH; Elhamri M; Thomas X
Leuk Res; 2003 Mar; 27(3):205-14. PubMed ID: 12537972
[TBL] [Abstract][Full Text] [Related]
28. [Clinical characteristics and outcomes of 59 patients with acute lymphoblastic leukemia positive for BCR/ABL].
Liu Z; Liu XL; Du QF; Xu N; Zhong M; Song LL; Yi ZS; Liu QF; Meng FY; Zhou SY
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Mar; 29(3):512-5. PubMed ID: 19304540
[TBL] [Abstract][Full Text] [Related]
29. [Long-term clinical effect of the CCLG-ALL2008 regimen in treatment of childhood acute lymphoblastic leukemia with different molecular biological features].
Chen XJ; Zou Y; Liu XM; Yang WY; Guo Y; Ruan M; Liu F; Chen YM; Zhang L; Wang SC; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2019 Sep; 21(9):890-893. PubMed ID: 31506148
[TBL] [Abstract][Full Text] [Related]
30. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
[TBL] [Abstract][Full Text] [Related]
31. [Influence of MRD Status in Newly Diagnosed MM Patients with VGPR and Above after Treatment on Clinical Prognosis].
Yu X; Zhang KJ; Wu XJ; Shi LJ; Lin HZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1631-1636. PubMed ID: 33067965
[TBL] [Abstract][Full Text] [Related]
32. [The Clinical Characteristics and Prognosis of Patients with Acute Myeloid Leukemia Combine Paroxysmal Nocturnal Hemoglobinuria].
Wen J; Wang H; Xie J; Li G; Li ZZ; Zhang XB; Shi R; Song YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1080-1084. PubMed ID: 34362485
[TBL] [Abstract][Full Text] [Related]
33. [Imatinib Combined with VP Low Dose Regiment for Treating Newly Diagnosed Adult Patients with Ph-positive ALL].
Liu K; Guo YL; Yao ZL; Jin XS; Zhang R; Han XP; Gao XN; Yu L; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Dec; 23(6):1560-3. PubMed ID: 26708871
[TBL] [Abstract][Full Text] [Related]
34. [Clinical analysis on adult acute T-lymphoblastic leukemia].
Zhang Q; Zhou CL; Fu MW; Wang JY; Lin D; Liu BC; Li W; Mi YC; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):478-82. PubMed ID: 22541122
[TBL] [Abstract][Full Text] [Related]
35. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
36. [Influence of Combination with 1q21 Amplification or-No in Patients with Newly Diagnosed MM on the Clinical Effecacy of Bortezomib-based induction chemotherapy and Long-Term Prognosis of Patients].
Gu WW; Wang JS; Mu K; Ren G
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1251-1255. PubMed ID: 32798407
[TBL] [Abstract][Full Text] [Related]
37. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
[TBL] [Abstract][Full Text] [Related]
38. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
Liu XM; Chen XJ; Zou Y; Wang SC; Wang M; Zhang L; Chen YM; Yang WY; Guo Y; Zhu XF
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):761-766. PubMed ID: 31594062
[No Abstract] [Full Text] [Related]
39. [Clinical study of imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.].
Li CX; Wu DP; Liu H; Liu YJ; Ma X; Wu XJ; Chen XC; Sun DP
Zhonghua Xue Ye Xue Za Zhi; 2010 Mar; 31(3):181-5. PubMed ID: 20510109
[TBL] [Abstract][Full Text] [Related]
40. Significance of myeloid antigen expression in precursor T lymphoblastic lymphoma.
Cai Y; Sun XF; Yan SL; Zhen ZJ; Xia Y; Ling JY
Chin J Cancer; 2010 Mar; 29(3):312-6. PubMed ID: 20193116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
